Public-registry trials using Obrixtamig that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers | Boehringer Ingelheim | Small Cell Lung Cancer | PHASE1 / PHASE2 | 24 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →